Jonathan David Schwartz files SEC Form 4 disclosures for ROCKET PHARMACEUTICALS, INC.. They have made 8 open-market trades across 1 company since 2022, most recently 2025-11-18.
CIK 0001726398
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 8 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| RCKT | 299,064 | $782K |
| TRHC | 60,806 | $638K |
| Total | $1.4M |
Shares reported on the most recent Form 4, priced at the 2025-11-20 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| RCKT | SELL | 2025-11-18 | 2025-11-20 | $2.98 | $8K | +18.0% | +24.7% | +21.9% |
| RCKT | SELL | 2025-08-18 | 2025-08-20 | $3.05 | $8K | -13.8% | -18.4% | -21.8% |
| RCKT | SELL | 2025-08-14 | 2025-08-18 | $3.02 | $34K | +10.6% | +0.0% | +0.3% |
| RCKT | SELL | 2025-05-20 | 2025-05-22 | $6.45 | $5K | -54.0% | -58.6% | -40.9% |
| RCKT | SELL | 2025-05-16 | 2025-05-20 | $6.53 | $10K | -58.5% | -59.6% | -54.6% |
| RCKT | SELL | 2024-05-17 | 2025-02-27 | $14.66 | $357K | -14.0% | -30.2% | -74.0% |
| RCKT | SELL | 2023-02-17 | 2023-02-22 | $19.06 | $136K | +6.9% | -13.4% | +15.6% |
| RCKT | SELL | 2022-03-30 | 2022-04-04 | $16.21 | $4.4M | -18.9% | -33.3% | -7.1% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.